Corona Remedies Ltd (CORONA)

📊 Quarterly Results (₹ Cr)

Revenue has grown sequentially from ₹342 crores (Dec 2025) to ₹361 crores (Sep 2025) to ₹353 crores (Mar 2026) to ₹422 crores (Jun 2026), indicating accelerating top-line momentum ahead of full commercialization of new facilities. Net profit rose sharply to ₹60 crores in Q1 FY27 from ₹45 crores in the prior quarter and ₹41 crores in December 2025, with OPM expanding to 18.9% from 14.7% in Q4 FY26, suggesting operating leverage and margin improvement from scale. This trajectory aligns with management's strategic investments in manufacturing infrastructure and brand integration, which they have linked to long-term growth in therapeutic segments with higher margins.

🔮 Management Outlook & What's Next

Management did not provide explicit forward guidance in the latest filing, but referenced 'forward-looking statements' with standard risk disclosures in the context of announcing Q1 FY27 results and the new facility launch. Prior communications have emphasized growth in women's health therapeutics, international market opportunities, and the scalability of the EU-GMP facility as a driver of future earnings. The integration of Wokadine and capacity expansion are positioned as catalysts for sustained growth, though no quantitative targets were disclosed in the available filings.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows stable equity of ₹61 crores with growing reserves (₹546 to ₹598 to ₹686 crores across recent filings), indicating retained earnings are being capitalized to support expansion. Borrowings remain low and declining (₹130 to ₹63 to ₹143 crores), with a recent reduction suggesting deleveraging or reduced need for external financing. Total assets have grown to ₹1,205 crores, driven by investments in fixed assets tied to the new manufacturing facility. This pattern reflects a capital-light growth strategy funded primarily through internal accruals and equity retention, with minimal reliance on debt.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 69%, suggesting confidence in long-term prospects. FII and DII ownership have increased significantly — FII from 1.84% (Q3FY26) to 3.63% (Q1FY27), and DII from 6.77% to 12.9% — indicating institutional accumulation. The number of shareholders has declined slightly (31,035 to 19,609 to 20,185), pointing to consolidation among investors. No promoter pledging or significant dilution is evident, and the rising institutional interest aligns with the company's strategic progress in high-growth therapeutic areas.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) The ₹19.10 crores exceptional item related to new labour codes in Q1 FY27 may distort comparability of underlying profitability, though management treats it as non-recurring. 2) Despite strong growth, the company remains concentrated in the domestic women's health segment, with limited diversification into other therapeutic areas or geographies. 3) High OPM expansion (18.9% in Q1 FY27) may be vulnerable to input cost pressures or competitive pricing if market dynamics shift. 4) The new EU-GMP facility is still in early commercialization, and execution risks in scaling operations or regulatory compliance could impact margins.

📋 Recent Filings

• Announcement2026-09-28Corona Remedies Ltd announced that its trading window will close on October 1, 2026, remaining shut until 48 hours after the unaudited Q2 results for …
• 🔴 Insider Trading2026-09-19Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,485,476; 51,641; and 92,763 shares of Corona Remedies Ltd respectively on…
• 🔴 Insider Trading2026-09-19Sepia Investments Limited, Sage Investment Trust and Anchor Partners sold a combined 2,630,880 shares of Corona Remedies Ltd on September 10, 2026, re…
• 🔴 Announcement2026-09-18Corona Remedies Ltd announced an analyst and investor meeting scheduled for September 23, 2026 at 2:00 pm in Ahmedabad, organized by JP Morgan, to dis…
• Announcement2026-09-10Corona Remedies clarified that recent share volume increases are purely market-driven with no undisclosed price-sensitive information or pending corpo…
• Announcement2026-08-20CORONA Remedies announced its officials will attend an in-person investor conference hosted by Phillip Capital PCG Group in Ahmedabad on August 26, 20…
• Announcement2026-08-10CORONA Remedies reported strong Q1 FY27 results with 21.9% YoY revenue growth driven by 22.7% India growth and 33.5% EBITDA growth, supported by 73.4%…
• 🔴 Financial Results2026-08-07CORONA Remedies Limited reported unaudited standalone revenue of [amount not verified] and consolidated net profit of **₹60.10 crores** for Q1 FY27, u…
• 🔴 Financial Results2026-08-03CORONA Remedies Limited announced that the audio recording of its Q1 FY27 earnings conference call for the quarter ended June 30, 2026 is now availabl…
• 🔴 Financial Results2026-07-22CORONA Remedies Limited announced its Q1 FY27 earnings conference call scheduled for August 3, 2026 at 11:30 a.m. IST to discuss financial results for…

🧠 Analyst's Read

Corona Remedies is executing a clear strategy to deepen its position in women's health through targeted investments and brand integration, supported by strong financial momentum and improving operational efficiency. Investors should monitor the commercial ramp-up of the new EU-GMP facility and the sustainability of margin expansion as key indicators of long-term growth quality.

Based on filing content and financial data. Not a recommendation.